An open label, single center study to assess the pharmacokinetics, safety and tolerability of multiple administrations of 30 mg PMI-150 (intranasal ketamine) in healthy adult volunteers

Trial Profile

An open label, single center study to assess the pharmacokinetics, safety and tolerability of multiple administrations of 30 mg PMI-150 (intranasal ketamine) in healthy adult volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2008

At a glance

  • Drugs Ketamine (Primary)
  • Indications Acute pain; Cancer pain
  • Focus Pharmacokinetics
  • Sponsors Javelin Pharmaceuticals
  • Most Recent Events

    • 13 Aug 2008 Pharmacokinetic data presented at the Department of Defense's 2008 Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference.
    • 31 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top